Published in Clin Res Cardiol on March 29, 2014
Rescue renal sympathetic denervation in a patient with ventricular electrical storm refractory to endo- and epicardial catheter ablation. Clin Res Cardiol (2014) 2.15
Renal denervation as a friend of catheter ablation in patients with atrial fibrillation and hypertension. Clin Res Cardiol (2014) 1.52
Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. Clin Res Cardiol (2016) 0.86
Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension. Clin Res Cardiol (2015) 0.83
Elevated M2-muscarinic and β1-adrenergic receptor autoantibody levels are associated with paroxysmal atrial fibrillation. Clin Res Cardiol (2014) 0.80
Renal sympathetic denervation for treatment of ventricular arrhythmias: a review on current experimental and clinical findings. Clin Res Cardiol (2015) 0.79
Atrial fibrillation and long-term sports practice: epidemiology and mechanisms. Clin Res Cardiol (2014) 0.79
Renal denervation for treatment of hypertension and beyond. Clin Res Cardiol (2014) 0.78
Renal artery sympathetic denervation: observations from the UK experience. Clin Res Cardiol (2016) 0.77
Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation. Clin Res Cardiol (2015) 0.76
Obstructive sleep apnea and atrial arrhythmogenesis. Curr Cardiol Rev (2014) 0.75
Single-sided renal denervation may be not suitable for patients with significant renal artery stenosis. Clin Res Cardiol (2014) 0.75
Second denervation in a patient with resistant hypertension. Clin Res Cardiol (2016) 0.75
Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation (1998) 19.93
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet (2010) 14.40
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation (2006) 11.78
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet (2009) 10.53
Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med (1984) 6.74
Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol (2009) 6.58
Physiology of local renin-angiotensin systems. Physiol Rev (2006) 5.77
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med (2002) 5.55
Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation (1999) 4.24
Stroke severity in atrial fibrillation. The Framingham Study. Stroke (1996) 4.11
Neural control of renal function. Physiol Rev (1997) 4.00
Association of atrial fibrillation and obstructive sleep apnea. Circulation (2004) 3.81
Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation (1990) 3.72
A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol (2012) 3.57
Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation (2013) 3.44
Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins: lessons from double Lasso technique. Circulation (2004) 3.20
Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke (2005) 3.07
Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation (2003) 2.99
Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev (2011) 2.78
Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart (2001) 2.78
Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension (2011) 2.68
Left stellate ganglion and vagal nerve activity and cardiac arrhythmias in ambulatory dogs with pacing-induced congestive heart failure. J Am Coll Cardiol (2007) 2.46
Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation (1986) 2.38
Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation (2009) 2.26
Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. Circ Arrhythm Electrophysiol (2009) 2.19
Quality of life in patients with atrial fibrillation: a systematic review. Am J Med (2006) 2.17
Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation (2003) 2.16
Renal sympathetic denervation as an adjunct to catheter ablation for the treatment of ventricular electrical storm in the setting of acute myocardial infarction. J Cardiovasc Electrophysiol (2013) 2.12
Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors. J Intern Med (2001) 2.12
Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. J Am Coll Cardiol (2013) 2.12
Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol (2004) 2.10
Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy. J Am Coll Cardiol (2006) 2.06
Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation (1998) 2.04
Selective ganglionated plexi ablation for paroxysmal atrial fibrillation. Heart Rhythm (2009) 2.02
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA (2006) 2.00
Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J (2013) 1.90
Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol (2009) 1.88
Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J (2005) 1.80
Atrial remodeling in obstructive sleep apnea: implications for atrial fibrillation. Heart Rhythm (2011) 1.80
Roles of adrenergic and cholinergic stimulation in spontaneous atrial fibrillation in dogs. J Am Coll Cardiol (2004) 1.79
Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. Int J Cardiol (2012) 1.71
Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation (2011) 1.67
Improvements in left ventricular hypertrophy and diastolic function following renal denervation: effects beyond blood pressure and heart rate reduction. J Am Coll Cardiol (2013) 1.63
Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol (2011) 1.58
Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol (2000) 1.58
Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension (2012) 1.52
A comparison of atrial arrhythmias after heart or double-lung transplantation at a single center: insights into the mechanism of post-operative atrial fibrillation. J Am Coll Cardiol (2009) 1.51
Outcome of anatomic ganglionated plexi ablation to treat paroxysmal atrial fibrillation: a 3-year follow-up study. Europace (2010) 1.50
Combined blockade of early and late activated atrial potassium currents suppresses atrial fibrillation in a pig model of obstructive apnea. Heart Rhythm (2011) 1.43
Atrial fibrillation produced by prolonged rapid atrial pacing is associated with heterogeneous changes in atrial sympathetic innervation. Circulation (2000) 1.42
Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol (2011) 1.36
Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension (2012) 1.35
Effects of selective vagal and stellate ganglion stimulation of atrial refractoriness. Cardiovasc Res (1974) 1.28
Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs. Heart Rhythm (2013) 1.21
Functional role of renal afferents. Physiol Rev (1991) 1.13
Radiofrequency catheter ablation in unusual mechanisms of atrial fibrillation: report of three cases. J Cardiovasc Electrophysiol (1994) 1.13
Renal sympathetic denervation provides ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation. Hypertension (2012) 1.09
Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens (2008) 1.08
Negative tracheal pressure during obstructive respiratory events promotes atrial fibrillation by vagal activation. Heart Rhythm (2011) 1.06
Regional norepinephrine turnover in human hypertension. Clin Exp Hypertens A (1989) 1.05
Hypertension and atrial fibrillation: evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. Heart Rhythm (2010) 1.03
Effect of renal denervation on neurohumoral activation triggering atrial fibrillation in obstructive sleep apnea. Hypertension (2013) 1.03
Relation of the severity of obstructive sleep apnea in response to anti-arrhythmic drugs in patients with atrial fibrillation or atrial flutter. Am J Cardiol (2012) 1.01
Atrial fibrillation and stroke. Mortality and causes of death after the first acute ischemic stroke. Stroke (1997) 1.01
Effect of beta-blockers on free radical-induced cardiac contractile dysfunction. Circulation (1999) 0.97
Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function. Eur Heart J (2008) 0.96
Catheter-based renal sympathetic denervation significantly inhibits atrial fibrillation induced by electrical stimulation of the left stellate ganglion and rapid atrial pacing. PLoS One (2013) 0.93
Atrial autonomic innervation: a target for interventional antiarrhythmic therapy? J Am Coll Cardiol (2013) 0.93
Aldosterone promotes atrial fibrillation. Eur Heart J (2011) 0.91
Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. Am Heart J (1987) 0.90
The Tel Aviv Stroke Registry. 3600 consecutive patients. Stroke (1996) 0.90
Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat. Circulation (2005) 0.86
Adjunctive renal sympathetic denervation to modify hypertension as upstream therapy in the treatment of atrial fibrillation (H-FIB) study: clinical background and study design. J Cardiovasc Electrophysiol (2013) 0.85
Douglas P. Zipes Lecture. Neural mechanisms of atrial fibrillation. Heart Rhythm (2006) 0.85
Obstructive sleep apnea is a risk factor for stroke and atrial fibrillation. Chest (2010) 0.84
Renal artery ablation instead of pulmonary vein ablation in a hypertensive patient with symptomatic, drug-resistant, persistent atrial fibrillation. Clin Res Cardiol (2012) 0.81
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet (2010) 14.40
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med (2005) 12.03
Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med (2012) 9.22
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res (2002) 4.86
Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci U S A (2005) 4.13
Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med (2006) 4.07
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol (2012) 3.56
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation (2002) 3.48
Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice. J Clin Invest (2009) 3.45
Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation (2013) 3.44
Treatment strategies for resistant arterial hypertension. Dtsch Arztebl Int (2011) 3.32
Update on myocarditis. J Am Coll Cardiol (2012) 3.12
Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation (2011) 2.88
Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation (2011) 2.87
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J (2016) 2.70
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens (2009) 2.68
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press (2013) 2.62
Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation (2003) 2.59
PITX2c is expressed in the adult left atrium, and reducing Pitx2c expression promotes atrial fibrillation inducibility and complex changes in gene expression. Circ Cardiovasc Genet (2011) 2.56
Electropathological substrate of longstanding persistent atrial fibrillation in patients with structural heart disease: epicardial breakthrough. Circulation (2010) 2.56
Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol (2002) 2.54
Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural heart disease: longitudinal dissociation. Circ Arrhythm Electrophysiol (2010) 2.51
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J (2011) 2.44
Cardiomyocytes of noncardiac origin in myocardial biopsies of human transplanted hearts. Circulation (2002) 2.38
Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med (2009) 2.28
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation (2005) 2.25
Renal denervation in moderate to severe CKD. J Am Soc Nephrol (2012) 2.21
Physical activity improves long-term stroke outcome via endothelial nitric oxide synthase-dependent augmentation of neovascularization and cerebral blood flow. Circ Res (2006) 2.21
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol (2009) 2.20
Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J (2010) 2.12
Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation (2012) 2.07
Predictors of outcome in patients with suspected myocarditis. Circulation (2008) 2.03
Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol (2003) 2.01
Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2007) 1.99
Pulsatile venoarterial perfusion using a novel synchronized cardiac assist device augments coronary artery blood flow during ventricular fibrillation. Artif Organs (2014) 1.99
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol (2012) 1.94
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). J Am Coll Cardiol (2010) 1.94
Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol (2012) 1.93
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J (2012) 1.93
CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol (2012) 1.92
Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J (2013) 1.90
Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol (2002) 1.89
Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J (2012) 1.89
Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol (2010) 1.88
Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther (2002) 1.84
Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol (2003) 1.82
Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. Circulation (2012) 1.81
Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens (2011) 1.80
Modulation of antioxidant enzyme expression and function by estrogen. Circ Res (2003) 1.79
Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol (2002) 1.79
Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. Eur J Heart Fail (2009) 1.78
Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation (2003) 1.77
Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation (2004) 1.76
Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. Int J Cardiol (2012) 1.71
Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol (2010) 1.70
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J (2006) 1.68
Vascular effects of diet supplementation with plant sterols. J Am Coll Cardiol (2008) 1.68
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J (2015) 1.68
Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Am Heart J (2012) 1.65
Physical exercise prevents cellular senescence in circulating leukocytes and in the vessel wall. Circulation (2009) 1.63
Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation (2011) 1.62
Elevated cytosolic Na+ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes. Circulation (2010) 1.61
Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation (2003) 1.61
Aneurysms of the ascending aorta. Dtsch Arztebl Int (2012) 1.60
Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. Heart Rhythm (2010) 1.59
Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol (2011) 1.58
Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort. Europace (2011) 1.57
Pioglitazone activates aortic telomerase and prevents stress-induced endothelial apoptosis. Atherosclerosis (2011) 1.56
Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation (2004) 1.56